Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Interest & Investment Income data on file, last reported at $5.2 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 39.5% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $25.8 million, a 41.07% decrease from a year earlier, with the FY2025 full-year figure at $29.2 million, down 38.93% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $5.2 million, down from $6.5 million in the prior quarter.
• Over the last five years, Interest & Investment Income for NTLA reached as high as $12.7 million in Q3 2023 and fell as low as $540000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $8.3 million across 5 years, with a median of $8.6 million in 2025.
• Across the five-year window, Interest & Investment Income surged 2118.52% in 2023 and tumbled 44.61% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $5.4 million in 2022, then surged by 132.7% to $12.5 million in 2023, then decreased by 14.67% to $10.6 million in 2024, then tumbled by 39.08% to $6.5 million in 2025, then retreated by 19.63% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $5.2 million in Q1 2026, $6.5 million in Q4 2025, and $6.7 million in Q3 2025.